VOSTALLY : HYPERTENSION AND CARDIOVASCULAR RISK REDUCTION TREATMENT

Vostally (Ramipril) is an angiotensin-converting enzyme (ACE) inhibitor widely used in the
management of hypertension, heart failure, and for cardiovascular risk reduction in high-risk
patients. It acts by inhibiting the conversion of angiotensin I to angiotensin II, a potent
vasoconstrictor, leading to vasodilation, decreased blood pressure, and reduced cardiac workload.
Additionally, ramipril lowers aldosterone secretion, reducing sodium and water retention, thereby
contributing to its antihypertensive and cardioprotective effects.
Vostally is indicated for the treatment of essential hypertension, management of heart failure postmyocardial infarction, and reduction of the risk of stroke, myocardial infarction, and
cardiovascular mortality in patients with established cardiovascular disease or diabetes with
additional risk factors. The drug is administered orally, usually as a once-daily dose, and
undergoes hepatic conversion to its active metabolite, ramiprilat.
Regular monitoring of renal function and serum electrolytes is essential during therapy.
Vostally’s proven efficacy in reducing blood pressure and preventing major Its use is supported
by major clinical guidelines for the treatment of hypertension and heart failure.
Keywords: Vostally, Ramipril, ACE inhibitor, Hypertension, Heart failure, Cardiovascular risk,
Vasodilation, Aldosterone, Ramiprilat.